Clinical development failure
Drug candidates may not show sufficient safety or efficacy, which would halt programs and reduce value.
- Scope
- Lead programs and future pipeline assets
- Materiality
- high
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics is a biotechnology company developing small-molecule molecular glue degraders (MGDs) that use the cell’s own protein-destruction machinery to selectively remove disease-driving proteins. The company’s platform is built around its QuEEN discovery engine and is focused on targets with strong biological and genetic rationale, with research operations in Boston and Basel.
−37,1 %
−31,2 %
+63,5 %
6.12
6.12
| % | |
|---|---|
| Molecular glue degraders | 70% Small-molecule therapeutics designed to recruit E3 ligases and degrade disease-relevant proteins. |
| Discovery platform | 10% QuEEN-enabled target identification, screening, and rational design capabilities used to generate candidates. |
| Collaboration revenue | 20% Revenue from partnered research and licensing arrangements, including the Novartis agreement. |
Monte Rosa does not sell to traditional end-market consumers; its direct counterparties are pharmaceutical partners...
- Pharmaceutical collaboration partnersprimary
Buy access to Monte Rosa’s discovery platform, target selection, and partnered programs to accelerate drug development.
- Future commercial patientsprimary
Would use approved MGD medicines if the company successfully develops and launches products.
- Healthcare providerssecondary
Prescribe or administer any approved therapies and influence adoption through treatment protocols.
- Research and development partnerssecondary
Engage in co-development or licensing arrangements around specific targets and discovery assets.
Monte Rosa is headquartered in Boston, Massachusetts and maintains research operations in both Boston and Basel,...
- •Headquartered in Boston, Massachusetts
- •Research operations in Boston and Basel, Switzerland
- •Swiss operating subsidiary supports R&D activity
- •Foreign clinical trials may add regulatory and execution risk
- •No country-level revenue disclosure was provided
The company’s strategy is to use its QuEEN platform to identify high-confidence targets and build a differentiated...
01
Advance lead MGD programs into the clinicshort-term
Clinical data are needed to validate the platform and create long-term value.
02
Expand and refine the QuEEN discovery enginemedium-term
A stronger platform should improve hit generation, selectivity, and pipeline productivity.
03
Build strategic collaborations and licensing revenuemedium-term
Partnerships can offset R&D spend and validate the technology externally.
Monte Rosa is a pre-commercial biotech, so its value depends heavily on successful preclinical and clinical execution,...
Regulatory approval risk
Even promising candidates may not obtain clearance or marketing approval on time, or at all.
- Scope
- All product candidates
- Materiality
- high
Financing and liquidity risk
The company expects continued losses and may need additional capital to fund R&D and trials.
- Scope
- Operating runway and development spend
- Materiality
- high
Foreign clinical trial execution
Trials outside the U.S. can face protocol adherence issues, administrative burdens, and local political risk.
- Scope
- International clinical studies
- Materiality
- medium
Third-party collaboration risk
Partners may be unwilling or unable to meet contractual obligations, affecting revenue and program progress.
- Scope
- Licensing and collaboration agreements
- Materiality
- medium
Revenue recognition for collaboration agreements
2025 Novartis Agreement and other licensing/collaboration revenue
Deferred revenue
Reported revenue and balance sheet liabilities
R&D accrual estimates
Operating expenses and net loss
Stock-based compensation
GAAP operating loss and dilution analysis
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
MUSTANG BIO, INC.
MBIO · Pharmaceutical Preparations
: 28/04/2026